Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC)
Michael Robert Migden
Consultant or Advisory Role - Novartis
Honoraria - Genentech; Lilly; Novartis
Research Funding - Genentech
Expert Testimony - Novartis (U)
Other Remuneration - Novartis
Alexander David Guminski
Consultant or Advisory Role - Novartis
Ralf Gutzmer
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Research Funding - Novartis; Pfizer; Roche
Other Remuneration - Bristol-Myers Squibb; Roche
Luc Yves Dirix
No relevant relationships to disclose
Karl D. Lewis
No relevant relationships to disclose
Patrick Combemale
No relevant relationships to disclose
Robert Herd
No relevant relationships to disclose
Sven Gogov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Tingting Yi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Manisha Mone
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ragini Reiney Kudchadkar
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech
Honoraria - Bristol-Myers Squibb; Genentech
Uwe Trefzer
Consultant or Advisory Role - Roche
Honoraria - Roche
John Lear
Honoraria - Novartis
Dalila B. Sellami
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Reinhard Dummer
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche
Research Funding - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche